Psychedelic Therapy in Switzerland: Every Legal Route (2026)

If you are considering psychedelic-assisted treatment in Switzerland — for yourself or for someone close to you — four legal routes exist in July 2026, and one of them exists nowhere else in Europe: a limited medical use program under which individually authorized physicians treat patients with psilocybin, LSD or MDMA when standard treatments have failed. The other three are reimbursed esketamine at officially designated centers, private off-label ketamine, and clinical trials. Every route is gated by your documented treatment history, so the most useful preparation is a written list of every treatment you have tried, with dose, duration and outcome; you can begin orienting yourself with our eligibility check.

TL;DR Spravato is reimbursed by basic insurance (OKP) for severe treatment-resistant depression, but only at the 52 BAG-designated centers, only after your insurer's trust doctor approves a cost request, and for a maximum of 10 months (extendable twice by 3 months). The Limitatio requires at least 2 failed antidepressants plus a failed augmentation attempt and CGI-S severity of 5 or more. Separately, authorized psychiatrists may treat named patients with psilocybin, LSD or MDMA under the limited medical use program — around 100 physicians and 723 patients in 2024, usually self-paid, with waitlists of many months. Private ketamine runs CHF 300–500 per infusion, and Basel and Zurich anchor one of Europe's densest trial scenes.

At a glance

Route	Substance	Status in Switzerland	Who qualifies	Cost
Reimbursed esketamine	Esketamine (Spravato)	On the Spezialitätenliste since 1 October 2025 (temporary limitations to 30 September 2028); running at 52 designated centers	Age 18–74, severe treatment-resistant depression, 2 failed antidepressants plus 1 failed augmentation, CGI-S 5+, ECT not indicated, refused or not accessible	Covered by OKP after trust-doctor pre-approval; 10-month cap
Limited medical use	Psilocybin, LSD, MDMA	Legal under Article 8 Narcotics Act exceptional-use permits; about 100 authorized physicians	Serious condition with standard treatments exhausted, accepted by an authorized psychiatrist for a named-patient permit	Usually self-paid
Private ketamine	Ketamine (off-label)	Legal	Off-label decision after medical screening	~CHF 300–500 per infusion, self-pay
Clinical trials	LSD, MDMA, psilocybin, DMT, ketamine, others	73 trials tracked, 15 active; several recruiting	Study-specific criteria	Free

Esketamine (Spravato): reimbursed, but only at designated centers

Spravato entered the Spezialitätenliste on 1 October 2025 with temporary limitations running to 30 September 2028, under a strict Limitatio. Per the BAG listing documentation and the standard insurer request form, reimbursement requires:

Age 18–74 with a severe treatment-resistant episode of major depression;
Failure of at least 2 different antidepressants plus 1 augmentation attempt (lithium or an atypical antipsychotic) at adequate dose and duration;
Severity of CGI-S 5 or higher;
Electroconvulsive therapy currently not indicated, refused, or not accessible;
Use in combination with an oral antidepressant.

Where and how. Prescribing is restricted to psychiatrists at the 52 centers designated by the BAG — institutions with a cantonal mandate for adult psychiatric care. Before the first dose, the center submits a cost approval request (Kostengutsprache) to your insurer, reviewed by the trust doctor (Vertrauensarzt). Practically: ask your psychiatrist for a referral to the nearest listed center, bring a complete medication history, and budget some weeks for the pre-approval step.

The time limit. Coverage runs for a maximum of 10 months, extendable at most twice by 3 months each when continued response is documented. Discuss the maintenance and exit strategy at the start, not at month nine. For how Switzerland's arrangements compare with the rest of the continent, see our Europe-wide reimbursement map.

Access pathway in Switzerland: diagnosis by a psychiatrist, referral to a designated center, the center's own eligibility check, reimbursed treatment under the national program

Psilocybin, LSD and MDMA: the limited medical use program

This is the Swiss specialty. Under Article 8 of the Narcotics Act, the Federal Office of Public Health (FOPH/BAG) can grant exceptional case-by-case authorizations for the medical use of otherwise prohibited substances. A physician applies for a named patient, justifying that the condition is serious, standard treatments have been exhausted, and the substance may relieve suffering. MDMA and LSD have been available this way since 2014, psilocybin since 2021 (program history, peer-reviewed).

The scale is meaningful but controlled. In 2024, about 100 physicians held authorizations covering 723 patients — MDMA mostly for PTSD, psilocybin mostly for depression and end-of-life distress — typically 2–4 dosing sessions per patient within 12 months, embedded in ongoing psychotherapy. A 2025 BAG-commissioned expert report confirms the same picture: roughly 700 permits granted in 2024 across around 100 treating physicians, with psilocybin the most requested substance and permit numbers rising every year since 2021. How a patient realistically gets in:

Access runs through the physician, not the BAG. You cannot apply yourself; you need an authorized (or willing-to-apply) psychiatrist to take you on, and the permit is issued for you by name, with your consent. There is no public directory of permit holders, so the realistic path is a referral from your treating psychiatrist to a practice experienced with the program. Waitlists at such practices commonly run many months.
Costs are usually private. These treatments are not on the Spezialitätenliste and basic insurance does not routinely pay. Budget for preparation sessions, supervised dosing days of 6+ hours, and integration sessions.
It is designed for patients in Swiss care. Authorizations are physician- and patient-specific, applications involve Swiss residency requirements, and providers require the ability to attend multiple in-person visits — cross-border "therapy tourism" is not what the program is for.
It is not a single-session cure. Expect a treatment arc over months inside an ongoing psychotherapy, not a standalone appointment. Note also that this FOPH permit route is the pathway: the 2025 expert report states Switzerland had no separate Swissmedic compassionate-use program for psychedelics in operation.

Ketamine: private off-label infusions

Licensed physicians may also offer off-label ketamine privately, typically around CHF 300–500 per infusion. Reimbursement is the exception, not the rule: FOPH commentary from 2023 records that a request to add ketamine to the reimbursement annex for depression and pain was rejected, so psychiatric ketamine remains essentially self-pay (Blossom's Switzerland access guide). Verify cantonal practice authorization via MedReg and apply the usual clinic-choice checks: psychiatric and cardiovascular screening before payment, a physician present during sessions, and measured outcomes.

Clinical trials in Switzerland

The research route is denser here than almost anywhere in Europe: Blossom tracks 73 psychedelic trials connected to Switzerland, 15 of them active (Blossom's Switzerland report). Basel — above all University Hospital Basel — anchors clinical pharmacology and patient studies, while Zurich focuses on neuroimaging and translational psychiatry; Geneva and Bern also run programs. Currently recruiting studies include Phase 1 work on intravenous 5-MeO-DMT and on MDMA for experimentally induced pain, plus a pharmacokinetic comparison of an LSD derivative with LSD; many Swiss trials enrol healthy volunteers, with patient studies in depression, alcohol use disorder and palliative distress. Participation is free and legal, but screening is strict and enrolment is never guaranteed. See the trials guide for how phases, placebo and consent work, and search ClinicalTrials.gov for current listings.

What to expect in treatment

Whichever route you take, the shape of care is similar and worth picturing in advance. It starts with a screening appointment: the clinician reviews your psychiatric and medication history, checks your cardiovascular health and current medicines, and confirms the diagnosis before anything is scheduled. This is also where contraindications are caught.

On a Spravato day at a designated center you self-administer the nasal spray under supervision, then stay for an observation period of roughly two hours while staff monitor blood pressure, heart rate and how you feel; dissociation and a temporary rise in blood pressure are expected and settle as the drug clears. You must not drive until the next day, so arrange a ride home. Treatment is always combined with a continuing oral antidepressant, and frequency typically tapers based on measured response.

A ketamine infusion is usually given intravenously over about 40–60 minutes with the same vital-sign monitoring and a recovery period afterwards. In the limited medical use program, dosing days are long — commonly 6+ hours of supervised experience — and are embedded in preparation beforehand and integration sessions afterwards, within an ongoing psychotherapy. In every setting the medicine is one part of the plan: screening, monitoring and follow-up are what make it safe.

Risks and who should not start

These treatments are generally well tolerated under supervision, but they are not for everyone — which is exactly what screening is for. Common, transient effects during or shortly after a session include dissociation (a detached, dreamlike feeling), nausea, mild perceptual changes, and a short-lived rise in blood pressure and heart rate; these resolve as the drug is metabolised. Treatment may be inappropriate, or require particular caution and specialist evaluation, when any of the following apply:

Uncontrolled hypertension or significant cardiovascular instability, including a history of aneurysmal vascular disease, because of the temporary rise in blood pressure.
A personal or family history of psychosis or bipolar disorder — a particular caution for classic psychedelics such as psilocybin, LSD and MDMA, where program physicians screen carefully.
Pregnancy or breastfeeding.
Substance-use concerns, particularly patterns of compulsive use.

A responsible provider screens for all of these before the first dose. If anyone offers to treat you without that assessment, treat it as a warning sign. To see who is listed near you, browse providers in Switzerland.

Frequently asked questions

Do I have to try ECT before Spravato is covered?

No — the Limitatio requires that ECT is currently not indicated, is refused by you, or is not accessible. Your psychiatrist documents which applies.

What happens when the 10-month cap is reached?

Coverage ends after at most two 3-month extensions. Continuation would be self-paid; discuss the maintenance and exit strategy with your psychiatrist at the start, not at month nine.

How do I find a physician authorized for psilocybin, LSD or MDMA therapy?

There is no public list of permit-holding physicians, and you cannot apply to the BAG yourself. Ask your treating psychiatrist for a referral to a practice experienced with the limited medical use program, expect a waitlist of many months, and be wary of anyone advertising fast access. You can also browse providers in Switzerland to see who is listed.

Can foreigners come to Switzerland for MDMA or psilocybin therapy?

The program is designed for patients within Swiss care: authorizations are physician- and patient-specific, applications involve residency requirements, and most providers require local follow-up. Exceptions are rare — be cautious of anyone advertising easy access.

Are psilocybin retreats in Switzerland legal?

No. Outside limited medical use authorizations and clinical trials, psilocybin remains prohibited. Retreat-style offerings without a BAG authorization are illegal, whatever their marketing says.

How long is a session, and can I drive afterwards?

For Spravato, budget most of a morning or afternoon: a short administration plus a roughly two-hour observation. A ketamine infusion runs about 40–60 minutes plus recovery. Program dosing days with psilocybin, LSD or MDMA commonly last 6+ hours. In every case you should not drive until the next day, so plan a lift home.

Sources

This guide is for general information only and is not medical advice, a diagnosis, or a recommendation of any treatment. Regulations and reimbursement rules change; always verify current requirements with the BAG, your insurer, and a licensed clinician who knows your history. If you are in crisis, contact your local emergency number or a crisis line immediately.

This guide awaits review by a licensed medical professional.

Psychedelic Therapy in Switzerland: Every Legal Route in 2026